Sign in
TerminatedNo phase

Remote Monitoring of the Diabetic Foot to Prevent Re-Ulceration

Key facts

Who runs it
Bluedrop Medical Limited
Where
Durham, United StatesSee the site
Trial code
Status
Terminated
People taking part
26 people enrolled
Started
22 Jan 2024
Ended
18 Sept 2024
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Bluedrop Monitoring Service (BMS)
Record updated
17 October 2024
Why it stopped
Unsustainable recruitment rate - too slow to enroll participants

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 23 criteriaShow less

Who can take part

  • Understanding of the study procedures and conditions of the protocol and agreement to participate in the study by providing consent prior to any study-specific procedures
  • Male or female patients 18 years or older
  • Diagnosis of type 1 or type 2 diabetes mellitus more than 3 months prior to the Screening Visit
  • History of healed diabetic foot ulcer(s), present for at least 2 weeks and healed within 2-24 months prior to screening
  • Confirmation of presence of peripheral neuropathy with loss of protective sensation (documented in medical records or certain ICD-10 codes for care of patients with diabetes and loss of protective sensation)
  • Patient has signed up for and provided or will provide consent to review of medical records available via the Pluto platform
  • Access to internet service at the site of device use or willing to use a 4G router provided by the Sponsor
  • Access to cell phone on which they can receive study communications
  • Has a healthcare provider who is confirmed to be their point of contact for foot care or injuries and this HCP uses an EHR that is compatible with Pluto
  • English speaking

Who cannot take part

  • Active foot infection or gangrene
  • Any history of major or minor lower limb amputation of more than 3 toes. NOTE: the hallux toe must be present on both feet to be eligible
  • Critical limb ischemia as evidenced by rest pain. NOTE: a healed ulcer indicates adequate perfusion and qualifies for the study
  • Any mental health disorder, psychiatric disorder, or alcohol or drug abuse history such that, in the opinion of the investigator, the patient is unreliable as a study participant
  • End-stage kidney disease (estimated GFR <15 mL/min/1.73 m2, and/or receiving renal replacement therapy)
  • Patients with active foot ulcers or other open foot lesions
  • Weight, when fully clothed, of greater than 150 kg
  • Active Charcot arthropathy defined as the phase where the foot is undergoing collapse
  • Known pregnancy at the time of enrollment.*
  • Any travel plans expected to result in an interruption of BMS use for greater than 30 consecutive days
  • Unable to identify and/or return to a usual care provider for foot care for the duration of the study
  • Unable or unwilling to be enrolled in the Pluto unified medical records system
  • Other issue that, at the discretion of the PI, renders the participant ineligible for participation. This includes inability to use the BMS for at least 3 days per week; Participants who become pregnant during the study will not be removed. Pregnancy will be noted in their mobile application profile and their participation in the study will be closely monitored

Where in United States

  • Duke Clinical Research InstituteDurham, United States

About the trial

What the trial wants to find out

The purpose of this study is to understand the effects of the Bluedrop Monitoring System (BMS) on the development of diabetic foot ulcers.

Read full original descriptionShow less

All Participants in this study will continue with their normal foot care and complete surveys with questions about their foot health every three months.

Participants selected to receive the Bluedrop Monitoring System (BMS) will place it in their home and stand on it once a day for 12 months. Participants will also need to answer questions about their general foot health and, if using the system, their experience using the device and monitoring service.

The 2 groups in the trial

  • Use of Bluedrop Monitoring ServiceTreatment being tested

    The BMS is made up of the Delta Foot Scanner (DFS) device, its accompanying Sentinel Review Interface (SRI) software and a Bluedrop virtual monitoring service. The DFS is intended to be used for 30 seconds, once per day, by a person in their home. It is important that while using the device that the participant continues with their routine foot care as recommended by their doctor.

    Treatment: Bluedrop Monitoring Service (BMS)

  • Standard of careNo study treatment, for comparison

    Participants continue with routine foot care as recommended by their doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Remote Use of Thermovisual Monitoring to Reduce the RAte of Re-Ulceration in PatientS at Risk of RecurrenT Diabetic Foot UlcERs
Record updated
17 October 2024